TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04139746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scleral Buckling
Description: Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage-Injection-Pneumoretinopexy
Description: According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
Study: NCT03306797

Intervention type: OTHER
Group type: OTHER
Intervention: STANDARD REHAB
Description: The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONICHAND
Description: The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture.
Study: NCT03021174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXCAP Exercise
Description: 12 weeks of at-home walking and resistance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education Control
Description: 12 weeks of implementing eating tips
Study: NCT01594437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCN-202
Description: Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One or two doses administered by intravenous infusion.
Study: NCT05184751

Intervention type: OTHER
Intervention: colonoscopy

Intervention type: OTHER
Intervention: colonoscopy
Study: NCT03218683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5991
Description: AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5991
Description: AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5991 + Venetoclax
Description: Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
Study: NCT03652922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reactivation Mismatch
Description: Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactivation Mismatch
Description: Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative.
Study: NCT00201539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: double dose Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
Study: NCT00503399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 µg/day sc for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35 mg/week po for 18 months
Study: NCT00982566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
Study: NCT03806946

Intervention type: OTHER
Intervention: psychometric scales for assesment socioeconomic and behaviour problems
Description: to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden

Intervention type: OTHER
Intervention: psychometric scales for assesment socioeconomic and behaviour problems
Description: to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
Study: NCT04394741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control-Dry Needling
Description: Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles~1 session in upper trapezius muscle moving the needle up and down ten times.
Study: NCT02826148

Intervention type: OTHER
Group type: OTHER
Intervention: RAADS-R scale
Description: This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
Study: NCT00862953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal protein energy-restricted
Description: Normal protein diet energy restricted

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal protein energy-restricted
Description: Normal protein diet energy restricted

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein energy-restricted
Description: High protein diet, with either low or normal carbohydrate content

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein energy-restricted
Description: High protein diet, with either low or normal carbohydrate content
Study: NCT01713517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor residual insecticide spraying (IRS)
Description: Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
Study: NCT02965118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream Vehicle
Description: topical application
Study: NCT00287248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] IMPY & SPECT Imaging
Description: Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging
Study: NCT01993537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT01366651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.
Study: NCT01313923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (formerly known as Rapamycin)
Description: For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
Study: NCT03675841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazufloxacin Mesilate ear drops
Description: Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazufloxacin Mesilate ear drops
Description: Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazufloxacin Mesilate ear drops
Description: Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazufloxacin Mesilate ear drops
Description: Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
Study: NCT04336423

Intervention type: DIAGNOSTIC_TEST
Intervention: Obtain samples from sputum and feces
Description: Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
Study: NCT01713517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Lasting Insecticidal Nets (LLIN)
Description: Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Lasting Insecticidal Nets (LLIN)
Description: Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
Study: NCT02742688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyrus pyrifolia var. culta(Makino) NaKai peel extract
Description: Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(4g/day)
Study: NCT00376844

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Brachytherapy
Study: NCT00143507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Study: NCT03417882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRN-1201 + Pembrolizumab
Description: GRN-1201 will be administered in combination with Pembrolizumab
Study: NCT00982566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
Study: NCT00789074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Varenicline 1mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1mg BD
Study: NCT03674931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical practice
Description: Intensive weekly musical keyboard training over 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: music education
Description: Recreative weekly musical courses without practice over 12 months
Study: NCT00531687

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered
Study: NCT02208401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional cold snare polypectomy
Description: conventional cold snare polypectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy with suction
Description: Cold snare polypectomy with suction
Study: NCT01974765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
Study: NCT01407003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Participants will receive a single or multiple doses of LIK066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Participants will receive a single or multiple doses of LIK066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single or multiple doses of a matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single or multiple doses of a matching placebo
Study: NCT01915927

Intervention type: DRUG
Group type: OTHER
Intervention: MSC-AFP
Study: NCT03554265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Genotropin given by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Genotropin given by injection
Study: NCT04666077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based MT through Supervised, Supported Singing (H3S)
Description: Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based MT through Supervised, Supported Singing (H3S)
Description: Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Music Therapy (IMT)
Description: The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (AtCon)
Description: The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition.
Study: NCT02605837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (OBS)
Description: Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of 10 ml of placebo matched with the experimental drug.
Study: NCT00762424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flowmax
Description: 0.4 mg once a day until stone passage total = 9 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cornstarch
Study: NCT01546402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Drug delivery system (Ozurdex)
Description: It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.